Full-Time

Bioinformatics Scientist

Gene Regulation & Cellular Reprogramming

Updated on 5/20/2026

e184

e184

1-10 employees

VC funding HealthTech, FinTech, and SaaS

No salary listed

Portland, OR, USA

In Person

Category
Biology & Biotech (1)
Required Skills
Python
R
Git
Docker
Requirements
  • PhD in Bioinformatics, Computational Biology, or related quantitative field (or MS with 5+ years relevant industry experience)
  • Demonstrated track record applying computational transcription factor ranking and gene regulatory network inference to cellular reprogramming problems, transdifferentiation, directed differentiation, or induced pluripotent stem cell systems
  • Multi-platform single-cell RNA-seq expertise: hands-on analysis from at least two different platforms, including platform-specific troubleshooting and quality control
  • Multi-modal genomics proficiency: chromatin immunoprecipitation sequencing, chromatin profiling using cleavage under targets and release using nuclease, or assay for transposase-accessible chromatin sequencing analysis including peak calling, differential accessibility, and transcription factor motif enrichment
  • Hands-on experience with established gene regulatory network inference methods to nominate or rank regulators of cell state, beyond literature-curated lists
  • Experience analyzing pooled perturbation screens (CRISPR activation, CRISPR knockout, or barcoded transcription factor overexpression) with single-cell or bulk readouts
  • Working knowledge of trajectory inference and pseudotime methods for mapping cell state transitions
  • Strong programming skills in Python and R, with proficiency in Scanpy/Seurat and statistical analysis for high-dimensional data
  • Comfortable working in a modern computational environment: cloud platforms, workflow managers, containerization, and collaborative version control
  • Strong publication record and demonstrated cross-functional collaboration with experimental biologists
Responsibilities
  • Lead end-to-end transcription factor discovery for cellular reprogramming - from multi-platform single-cell genomics analysis (scRNA-seq, ATAC-seq) through gene regulatory network inference, differential analysis, and trajectory mapping - to nominate the regulators that flip cell fate
  • Crack the combinatorial code of reprogramming by ranking transcription factor cocktails as actionable combinations and decoding pooled perturbation and CRISPRa screens at single-cell resolution
  • Read regulatory grammar straight off the chromatin - accessibility, motifs, synergy, repression - and build the data backbone that harmonizes modalities and platforms into something we can actually model on
  • Sit shoulder-to-shoulder with wet lab teammates, closing the loop between predictions and screens: ingest fresh next-generation sequencing readouts, retrain, re-prioritize, and pick the next experiment that teaches the model the most
Desired Qualifications
  • Direct experience nominating or validating transcription factor cocktails that successfully induced a cell state conversion (published or in preparation)
  • Experience with dynamical systems modeling for cell state transitions, or inverse problem approaches for transcription factor combination ranking
  • Background in advanced trajectory inference (optimal transport, gene regulatory network dynamics over pseudotime), Bayesian genomics, multi-omics integration, or cross-species comparative regulatory genomics
  • Familiarity with transformer architectures in genomics and interest in hybrid classical/machine learning approaches to gene regulation

e184 is a venture capital investor focusing on HealthTech, FinTech, and SaaS in the United States, providing capital to startups to help them grow. It uses a multi-stage VC model, investing equity across early to late stages and aiming for exits such as IPOs or acquisitions, guided by leadership that coordinates capital allocation and leverages expertise in payments, banking, crypto, and investments. The firm differentiates itself through its sector focus combined with flexible stages and a willingness to explore additional verticals, using its payments, banking, and crypto know-how to guide portfolio value. Its goal is to deliver high-growth returns for investors by funding innovative startups, supporting their scale, and exiting positions profitably, while continually seeking new opportunities across industries.

Company Size

1-10

Company Stage

N/A

Total Funding

$5.8M

Headquarters

Kentucky

Founded

2023

Simplify Jobs

Simplify's Take

What believers are saying

  • Paterna BioSciences $6M seed round October 2024 validates e184's reproduction thesis and IVS market potential.[3][4]
  • SpringTide Ventures partnership in HealthTech opens co-investment synergies across digital health and life sciences.[3]
  • Neurotech moonshot program attracts entrepreneurial scientists seeking patient capital for long-horizon BMI development.[7]

What critics are saying

  • SpringTide Ventures leads Paterna round while e184 participates secondarily, reducing deal influence and returns.[3][4]
  • FDA approval delays for IVS technology post-2025 trials block portfolio exits and capital returns.[4][5]
  • Neuralink's rapid BMI advancement captures top talent and funding, starving e184's neurotech pipeline.[7]

What makes e184 unique

  • Multi-stage investor across HealthTech, FinTech, SaaS with deep sector expertise in payments, banking, crypto.[1][2]
  • Proprietary portfolio companies e184 BAI and e184 Repro-IVG provide direct exposure to neuroscience and reproduction.[1]
  • ARPA-inspired approach to neurotech moonshots emphasizes general-purpose tech over near-term applications.[7]

Help us improve and share your feedback! Did you find this helpful?

Your Connections

People at e184 who can refer or advise you

Benefits

Health Insurance

401(k) Retirement Plan

Paid Vacation

Remote Work Options

Flexible Work Hours

Wellness Program

Mental Health Support

Conference Attendance Budget

Professional Development Budget

Stock Options

Equity

Company News

EIN Presswire
Oct 28th, 2024
Paterna BioSciences Secures Seed Funding to Advance Groundbreaking Male Fertility Treatment

$6 million oversubscribed seed investment to advance pioneering in vitro spermatogenesis science, offers new hope for people struggling with infertility.